Inventor
COOLEN HEIN K A C
NL17 patents
⚠️ This page may combine multiple inventors who share the name “COOLEN HEIN K A C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABBVIE BV
5 patentsUS9951084B2Apr 24, 2018
Spiro-cyclic amine derivatives as S1P modulators
ABBVIE BV4 citations81
US10807991B2Oct 20, 2020
Spiro-cyclic amine derivatives as S1P modulators
ABBVIE BV2 citations70
US9670220B2Jun 6, 2017
Fused heterocyclic derivatives as S1P modulators
ABBVIE BV2 citations69
US9096612B2Aug 4, 2015
Fused heterocyclic derivatives as S1P modulators
ABBVIE BV2 citations59
USRE48301ENov 10, 2020
Fused heterocyclic derivatives as S1P modulators
ABBVIE BV0 citations38
STOIT AXEL
4 patentsUS8252930B2Aug 28, 2012
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
STOIT AXEL9 citations81
US10179791B2Jan 15, 2019
Spiro-cyclic amine derivatives as S1P modulators
STOIT AXEL3 citations69
US8586606B2Nov 19, 2013
Heterocyclic compounds with affinity to muscarinic receptors
STOIT AXEL0 citations49
US8084473B2Dec 27, 2011
Heterocyclic compounds with affinity to muscarinic receptors
STOIT AXEL0 citations45
SOLVAY PHARM BV
3 patentsUS7964728B2Jun 21, 2011
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
SOLVAY PHARM BV2 citations61
US7202238B2Apr 10, 2007
Diazabicyclo alkane derivatives with NK1 antagonistic activity
SOLVAY PHARM BV4 citations54
US7094779B2Aug 22, 2006
Piperazine oxime dervatives having NK-1 receptor antagonistic activity
SOLVAY PHARM BV0 citations36